News >

Fulvestrant/Anastrozole Combo Improves Survival in Metastatic HR+ Breast Cancer

Caroline Seymour
Published: Thursday, Mar 28, 2019

Rita S. Mehta, MD

Rita S. Mehta, MD

The frontline combination of fulvestrant (Faslodex) and anastrozole resulted in a sustained benefit in progression-free survival (PFS) and a significant improvement in overall survival (OS) compared with anastrozole alone in patients with postmenopausal, hormone receptor (HR)–positive metastatic breast cancer, according to long-term results of the SWOG S0226 trial (NCT00075764).1,2
... to read the full story
To Read the Full Story

View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Medical Crossfire®: Where Are We Headed in the Treatment of Triple-Negative Breast Cancer?Jul 31, 20191.5
Community Practice Connections™: Evolving Applications for PARP Inhibitors in Ovarian Cancer: Building on a Solid FoundationAug 15, 20191.5
Publication Bottom Border
Border Publication
x